Professor Martine Bagot and Professor Armand Bensussan are rewarded for their research on the development of a targeted therapy, lacutamab, a monoclonal antibody targeting the tumor antigen KIR3DL2 for the treatment of patients with advanced, refractory and relapsed T cell lymphomas, particularly erythrodermic cutaneous T cell lymphomas. The Galien Prize here rewards two decades of research.

18 December 2020

Armand Bensussan awarded the Galien Prize 2020
18 December 2020

Professor Martine Bagot and Professor Armand Bensussan are rewarded for their research on the development of a targeted therapy, lacutamab, a monoclonal antibody targeting the tumor antigen KIR3DL2 for the treatment of patients with advanced, refractory and relapsed T cell lymphomas, particularly erythrodermic cutaneous T cell lymphomas. The Galien Prize here rewards two decades of research.
[ Read more ]
17 December 2020

AACR annual meeting 2021
17 December 2020

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held virtually on April 10-15 and May 17-21, 2021.
[ Read more ]
15 December 2020

Season’s greetings
15 December 2020

From all of us at OREGA Biotech we wish you a wonderful holiday season and Merry Christmas !
[ Read more ]
16 October 2020

Anti CD39 mAb IPH5201 at EMSO 2020
16 October 2020

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours. Download abstract.
[ Read more ]